Compare MIRM & ABG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | ABG |
|---|---|---|
| Founded | 2018 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.5B |
| IPO Year | 2019 | N/A |
| Metric | MIRM | ABG |
|---|---|---|
| Price | $91.35 | $243.54 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | $97.55 | ★ $261.29 |
| AVG Volume (30 Days) | ★ 836.6K | 176.1K |
| Earning Date | 02-25-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.57 |
| EPS | N/A | ★ 28.52 |
| Revenue | $471,794,000.00 | ★ $17,827,000,000.00 |
| Revenue This Year | $54.25 | $6.67 |
| Revenue Next Year | $21.09 | $7.62 |
| P/E Ratio | ★ N/A | $8.58 |
| Revenue Growth | ★ 53.66 | 8.07 |
| 52 Week Low | $36.88 | $201.68 |
| 52 Week High | $93.70 | $312.56 |
| Indicator | MIRM | ABG |
|---|---|---|
| Relative Strength Index (RSI) | 71.95 | 53.19 |
| Support Level | $85.98 | $237.38 |
| Resistance Level | $93.70 | $252.13 |
| Average True Range (ATR) | 3.83 | 7.31 |
| MACD | 0.95 | 0.12 |
| Stochastic Oscillator | 87.40 | 58.37 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 152 new-vehicle stores and 37 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 14 states (mostly Texas, the West, the Mid-Atlantic, and the Southeast). Asbury store brands include McDavid and Park Place in Texas, Koons in the Washington, D.C. area, and the Larry H. Miller brand in the Western US. Asbury generated $17.2 billion of revenue in 2024 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.